Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersLori J. Wirth, Maria E. Cabanillas, Eric J. Sherman et al.|New England Journal of Medicine|2020Cited by 766
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II StudyJoshua Bauml, Robert I. Haddad, Jonathan D. Cheng et al.|Journal of Clinical Oncology|2017Cited by 653
Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in OncologyRobert I. Haddad, Susan Darlow, Lindsay Bischoff et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 507
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven CancersVivek Subbiah, Erica Evans, Joseph L. Kim et al.|Cancer Discovery|2018Cited by 392
NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018Robert I. Haddad, Lisa A. Gurski, Christian Nasr et al.|Journal of the National Comprehensive Cancer Network|2018Cited by 370